Search Videos and More
ESMO26: Antonio Giordano, MD, PhD, on FOURLIGHT
Antonio Gioradano, MD, presents efficacy and safety of atirmociclib + fulvestrant in HR+/HER2- advanced breast cancer after progressing on prior CDK4/6 inhibitor - data from phase 2 FOURLIGHT-1 study.ESMO26: Paolo Tarantino, MD on ADC Resistance in Breast Cancer
Paolo Tarantino, MD, of Dana-Farber Cancer Institute, shows that antibody-drug conjugate (ADC) resistance appears to be driven by complex molecular adaptations beyond target modulation.Turning Promise Into Progress
How new cancer treatments reach patients and help shape the next cycle of discoveryTreatment Guideline: First-Line Treatment of HER2-Positive Metastatic Breast Cancer
The Breast Oncology Center held meetings to discuss recommendations regarding first-line treatment of patients with HER2-positive metastatic breast cancer.ESMO Congress 2026
Preview news releases and presentations by Dana-Farber Physician-Scientists at this year's ESMO Congress 2026 in Madrid, Spain, October 23 - 27, 2026.Treatment Guideline: Elinzanetant in Patients with a Breast Cancer and Vasomotor Symptoms
The Breast Oncology Center held meetings to discuss recommendations regarding the use of elinzanetant in patients with a history of breast cancer and vasomotor symptoms.Novel Treatment Combination Improves Progression-Free Survival in Most Common Form of Metastatic Breast Cancer
Patients with estrogen-receptor-positive (ER+) HER-2-negative advanced breast cancer experienced significantly improved progression-free survival (PFS) when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist (SERD), compared to a standard combination approach.Building a System of Focused Care for Lobular Breast Cancer
How Dana-Farber investigators are pioneering new approaches to help understand, diagnose, and treat this distinct form of breast cancer2026 ASCO Breast Cancer Highlights: Triple Negative Breast Cancer
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new antibody drug conjugate treatment options in first line triple negative breast cancer.2026 ASCO Breast Cancer Highlights: BWEL
Harold Burstein, MD, PhD, and Jennifer A. Ligibel, MD discuss new research from the Breast Cancer Weight Loss (BWEL) trial, as well as recommendations for lifestyle, diet and GLP1 agonists.2026 ASCO Breast Cancer Highlights: HER2CLIMB-05
Harold Burstein, MD, PhD, and Adrienne Waks, MD discuss the HER2Climb-05 trial and how it impacts treatment for HER2+ metastatic breast cancer2026 ASCO Breast Cancer Highlights: Neo-Healer
Harold Burstein, MD, PhD, and Adrienne Waks, MD discuss the new Neo-Healer trial in HER2+ breast cancer.